Surmasis Reprimanded for Lab Records, Equipment Inspections

Drug GMP Report
The FDA hit Surmasis Pharmaceutical of Des Moines, Iowa with a Form 483 after a February inspection revealed problems with laboratory records, computer systems and equipment inspections.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $157.00